Researchers synthesise potential anticancer compounds
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
List view / Grid view
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) can block cell death, new research has shown, making it a cancer drug target.
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
Two screening techniques were used by researchers to find anticancer compounds that target the aryl hydrocarbon receptor.
Researchers have shown that topoisomerase TOP2A eliminates negative supercoiling, causing an increase in the number of turns of DNA strands and impacting gene expression.
Epithelial cell communication depends on the side of the cell, which could have implications for understanding how cancer spreads.
A combination of computer simulations and fragment screening have uncovered 27 molecular binding sites on tubulin, a protein of the cell cytoskeleton.
According to new research, the biochip market will grow as a result of the rising demand for personalised medicine.
Researchers have shown how the MIS hormone can prevent ovulation in females, making it a potential new form of contraception.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
A new study in cell cultures has shown that the sanguinarine plant compound could be used to treat people with triple-negative breast cancer.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.